Company Overview of Thallion Pharmaceuticals, Inc.
Thallion Pharmaceuticals Inc., a biotechnology company, engages in the development of pharmaceutical products in the areas of infectious diseases and oncology. Its lead product candidate includes Shigamabs, a dual antibody product that is in a Phase II clinical trial for the treatment of Shigatoxin-producing E. coli bacterial infections. The company also owns a proprietary technology platform, DECIPHER, a genomics-based discovery platform for identifying novel secondary metabolites from non-pathogenic microorganisms. Its other clinical program includes TLN-4601, a novel small molecule with potential to treat multiple cancer indications, including solid and liquid tumors. Thallion Pharmaceuti...
1375 TransCanada Highway
Dorval, QC H9P 2W8
Founded in 1998
Key Executives for Thallion Pharmaceuticals, Inc.
Thallion Pharmaceuticals, Inc. does not have any Key Executives recorded.
Thallion Pharmaceuticals, Inc. Key Developments
Thallion Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2013
Jul 25 13
Thallion Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2013. The company recorded a net loss and comprehensive loss attributable to equity holders of the company of $1,098,472 or $0.03 per basic and diluted share in the three-month period ended May 31, 201 3, compared with $723,971 or $0.02 per basic and diluted share in the corresponding period in 2012. Collaboration and licensing revenues were nil compared to $532,036 reported last year.
For the six-month period ended May 31, 2013, the company recorded net earnings and comprehensive income attributable to equity holders of the company of $7,673,340 or $0.24 per basic and diluted share, compared to a net loss and comprehensive loss attributable to equity holders of the company of $1,559,225 or $0.05 per basic and diluted share for the same period last year. This increase in net earnings in the first half of 2013 is largely attributable to the recognition of $9,656,256 in collaboration and licensing revenues as a result of the previously mentioned early termination of the development and license agreement with LFB. Collaboration and licensing revenues were $9,656,256 against $1,148,593 reported last year. Cash flows used in operating activities were $2,305,222 against $1,663,041 and additions to property and equipment were $941 against $1,003 reported last year.
Thallion Pharmaceuticals Inc. Elects Vic Alboini as Director
Jul 10 13
BELLUS Health Inc. and Thallion Pharmaceuticals Inc. announced that they have entered into an amendment to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement involving the acquisition of Thallion by BELLUS Health. Thallion also announced that concurrently with the entering into of the Voting Support Agreement, it has entered into an agreement with Jaguar Financial and Vic Alboini pursuant to which the Board of Directors of Thallion has filled the vacancy created by the recent departure of a Board member by electing Vic Alboini as a director of Thallion to hold office until the next annual meeting of shareholders or until his successor is elected or appointed, subject to the terms and conditions of such agreement.
Thallion Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended February 28, 2013; Announces Resignation of Roberto Bellini from the Board of Directors
Apr 24 13
Thallion Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended February 28, 2013. For the quarter, the company reported collaboration and licensing revenues of $9,656,256 compared to $616,557 a year ago. The increase in first quarter revenue is due to the early termination of the development and license agreement with LFB in February 2013; as the company will no longer be continuing the development of Shigamabs(r) under the agreement nor receiving any further payments, the deferred revenue balance was recognized as collaboration and licensing revenues in the first quarter of 2013. Net earnings were $8,771,812 or $0.27 per basic and diluted share compared with a net loss of $835,254 or $0.03 per basic and diluted share in the first quarter of 2012. This increase in net earnings is primarily due to the recognition of $9,656,256 in collaboration and licensing revenues. Cash used in operating activities was $843,147 compared to $1,054,539 a year ago. Additions to property and equipment was $941.
The company also announced that Mr. Roberto Bellini has resigned from the Board of Directors in order to pursue other interests. He had been a member of the company's Board since 2007.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|